Roche secured exclusive global rights to Simcere Zaiming’s SIM-0660, a preclinical trispecific T-cell engager targeting CD79a/CD19/CD3, in a potential $1.53 billion licensing deal. Roche will pay $75 million upfront and Simcere is eligible for development, regulatory, and commercial milestones, plus royalties. The molecule pairs a CD3-engaging arm with two B-cell targeting domains, designed to drive T-cell mediated killing of pathogenic B cells while limiting cytokine release—an area of past safety challenges for T-cell engager platforms. Strategically, the deal strengthens Roche’s B-cell disease franchise and signals continued investment into next-generation immune redirectors before IND-enabling progress.